Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 16, Issue 11, 2014, Pages 1087-1095

  Sha, S ^a   Polidori, D ^b   Heise, T ^c   Natarajan, J ^a   Farrell, K ^a   Wang, S S ^a   Sica, D ^d   Rothenberg, P ^a   Plum Morschel L ^c  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c Profil   (Germany)

^d VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antihypertensive therapy; Metformin; Pharmacodynamics; Phase I II study; SGLT2 inhibitor; Type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; CREATININE; GLUCOSE; HEMOGLOBIN; HEMOGLOBIN A1C; NITROGEN; PLACEBO; UREA; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; GLUCOSE BLOOD LEVEL; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; ELECTROLYTE BALANCE; FEMALE; FLUID BALANCE; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PLASMA VOLUME; POSITIONAL DIZZINESS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; URINE VOLUME; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; BLOOD; BODY WEIGHT; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIET RESTRICTION; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; HYPERTENSION; KIDNEY; METABOLISM; TREATMENT OUTCOME;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FASTING; FEMALE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; KIDNEY; MALE; METFORMIN; MIDDLE AGED; PLASMA VOLUME; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES; TREATMENT OUTCOME; WATER-ELECTROLYTE BALANCE; WEIGHT LOSS;

EID: 84914154997     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12322     Document Type: Article

References (34)

1. Stenlöf K, Cefalu WT, Kim K-A et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15: 372-382.
2. Schernthaner G, Gross JL, Rosenstock J et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care 2013; 36: 2508-2515.
3. Yale JF, Bakris G, Cariou B et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013; 15: 463-473.
4. Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 2013; 41: 72-84.
5. Cefalu WT, Leiter LA, Yoon K-H et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941-950.
6. Lavalle-González FJ, Januszewicz A, Davidson J et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013; 56: 2582-2592.
7. Wilding JP, Charpentier G, Hollander P et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013; 67: 1267-1282.
8. Stenlof K, Cefalu WT, Kim K-A et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin 2014; 30: 163-175.
9. Cefalu WT, Leiter LA, Yoon K-H et al. Canagliflozin (CANA) demonstrates durable glycemic improvements over 104 weeks versus glimepiride (GLIM) in subjects with type 2 diabetes mellitus (T2DM) on metformin (MET) (Abstract 65-LB). Diabetes 2013; 62(Suppl. 1): LB18.
10. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009; 75: 1272-1277.
11. Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin 2009; 25: 671-681.
12. Polidori D, Sha S, Ghosh A, Plum-Mörschel L, Heise T, Rothenberg P. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013; 98: E867-871.
13. Devineni D, Curtin CR, Polidori D et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 2013; 53: 601-610.
14. Rosenstock J, Aggarwal N, Polidori D et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 1232-1238.
15. INVOKANA™ (canagliflozin) tablets, for oral use [package insert]. Titusville, NJ: Janssen Pharmaceuticals, 2013.
16. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013; 15: 853-862.
17. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
18. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med 2013; 368: 1613-1624.
19. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007; 13: 9-20.
20. Haller M, Akbulut C, Brechtelsbauer H et al. Determination of plasma volume with indocyanine green in man. Life Sci 1993; 53: 1597-1604.
21. Jacob M, Conzen P, Finsterer U, Krafft A, Becker BF, Rehm M. Technical and physiological background of plasma volume measurement with indocyanine green: a clarification of misunderstandings. J Appl Physiol 2007; 102: 1235-1242.
22. Menth-Meier SE, Imoberdorf R, Regli B, Kipfer B, Turgay M, Ballmer PE. Determination of plasma volume by indocyanine green-validation of the method and use in patients after cardiopulmonary bypass. Intensive Care Med 2001; 27: 925-929.
23. Jacob M, Chappell D, Conzen P et al. Impact of the time window on plasma volume measurement with indocyanine green. Physiol Meas 2008; 29: 761-770.
24. Awni WM, Bakker LJ. Antipyrine, indocyanine green, and lorazepam determined in plasma by high-pressure liquid chromatography. Clin Chem 1989; 35: 2124-2126.
25. Polidori D, Rowley C. Optimal back-extrapolation method for estimating plasma volume in humans using the indocyanine green dilution method. Theor Biol Med Model 2014 (in press).
26. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
27. Gifford RWJ, Mattox VR, Orvis AL, Sones DA, Rosevear JW. Effect of thiazide diuretics on plasma volume, body electrolytes, and excretion of aldosterone in hypertension. Circulation 1961; 24: 1197-1205.
28. van Brummelen P, Schalekamp MA. Body fluid volumes and the response of renin and aldosterone to short- and long-term thiazide therapy of essential hypertension. Acta Med Scand 1980; 207: 259-264.
29. Guyton AC, Hall JE. Textbook of Medical Physiology. Philadelphia: Elsevier, Inc., 2010.
30. Hall KD, Sacks G, Chandramohan D et al. Quantification of the effect of energy imbalance on bodyweight. Lancet 2011; 378: 826-837.
31. Shah S, Khatri I, Freis ED. Mechanism of antihypertensive effect of thiazide diuretics. Am Heart J 1978; 95: 611-618.
32. Weidmann P, Beretta-Piccoli C, Keusch G et al. Sodium-volume factor, cardiovascular reactivity and hypotensive mechanism of diuretic therapy in mild hypertension associated with diabetes mellitus. Am J Med 1979; 67: 779-784.
33. Caulfield MJ, Munroe PB, O'Neill D et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 2008; 5: e197.
34. Weir MR, Januszewicz A, Gilbert R, Lavalle González F, Meininger G. Lower blood pressure (BP) with canagliflozin (CANA) in subjects with type 2 diabetes mellitus (T2DM) (Abstract 1077-P). Diabetes 2013; 62(Suppl. 1): A278.